Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15335102rdf:typepubmed:Citationlld:pubmed
pubmed-article:15335102lifeskim:mentionsumls-concept:C0917798lld:lifeskim
pubmed-article:15335102lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:15335102lifeskim:mentionsumls-concept:C2348867lld:lifeskim
pubmed-article:15335102pubmed:dateCreated2004-8-31lld:pubmed
pubmed-article:15335102pubmed:abstractTextSingle dose 3-nitropropionic acid (3-NPA) 24 hr before global ischemia improves neuronal survival in both, neocortex and hippocampus ('chemical preconditioning'). Neuronal survival after transient global ischemia requires new protein synthesis during recovery, especially of those with anti-apoptotic function. Bcl-2-protein is expressed in neurons that survive cerebral ischemia and may parallel the time course of tolerance after ischemic preconditioning. With this study we examined whether differences in bcl-2-protein expression compared to baseline may be involved in the induction of ischemic tolerance using 3-NPA. Male Wistar rats received either a single intraperitoneal (i.p.) dose of 3-NPA (20 mg/kg), and were observed for 3 (n = 4), 12 (n = 5) or 24 hours (n = 5) or the same amount of vehicle and were observed for 24 h (n = 8, controls). Immunohistochemistry allowed to compare the intensity of bcl-2 immunoreactivity at three subsequent time points in hippocampus, dentate gyrus and parietal neocortex with that of control animals. A single dose of 3-NPA caused a significant increase of bcl-2 protein immunoreactivity in hippocampal neurons, i.e. CA 1 (5 out of 5 animals, p = 0.003), CA 3 (5/5, p = 0.003), CA 4 (4/5, p = 0.025), and neocortex (5/5, p = 0.004), in a time dependent manner over a period of 24 hr after injection. Neuronal bcl-2 protein expression in CA 2 and dentate gyrus remained unchanged. The data suggest a possible role of bcl-2-protein in chemical induction of ischemic tolerance using a single subtoxic dose of 3-NPA. Bcl-2-protein expression may be initiated by increased levels of reactive oxygen species (ROS) after 3-NPA administration, as shown by others. Additional bcl-2 protein may then be available to (1) control postischemic ROS burst, (2) protect the mitochondrial membranes, and (3) inhibit pro-apoptotic mechanisms.lld:pubmed
pubmed-article:15335102pubmed:languageenglld:pubmed
pubmed-article:15335102pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15335102pubmed:citationSubsetIMlld:pubmed
pubmed-article:15335102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15335102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15335102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15335102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15335102pubmed:statusMEDLINElld:pubmed
pubmed-article:15335102pubmed:issn0065-1419lld:pubmed
pubmed-article:15335102pubmed:authorpubmed-author:KempskiOOlld:pubmed
pubmed-article:15335102pubmed:authorpubmed-author:HeimannAAlld:pubmed
pubmed-article:15335102pubmed:authorpubmed-author:BrambrinkA...lld:pubmed
pubmed-article:15335102pubmed:authorpubmed-author:AstheimerAAlld:pubmed
pubmed-article:15335102pubmed:authorpubmed-author:NogaHHlld:pubmed
pubmed-article:15335102pubmed:issnTypePrintlld:pubmed
pubmed-article:15335102pubmed:volume89lld:pubmed
pubmed-article:15335102pubmed:ownerNLMlld:pubmed
pubmed-article:15335102pubmed:authorsCompleteYlld:pubmed
pubmed-article:15335102pubmed:pagination63-6lld:pubmed
pubmed-article:15335102pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:meshHeadingpubmed-meshheading:15335102...lld:pubmed
pubmed-article:15335102pubmed:year2004lld:pubmed
pubmed-article:15335102pubmed:articleTitlePharmacological preconditioning in global cerebral ischemia.lld:pubmed
pubmed-article:15335102pubmed:affiliationInstitut of Neurosurgical Pathophysiology, Johannes Gutenberg-University, Mainz, Germany.lld:pubmed
pubmed-article:15335102pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15335102pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15335102pubmed:publicationTypeEvaluation Studieslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15335102lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15335102lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15335102lld:pubmed